Literature DB >> 11668500

Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas.

J H Yoon1, R Dammann, G P Pfeifer.   

Abstract

Homozygous deletion and loss of heterozygosity (LOH) at chromosome 3p21 have been observed in several types of human cancer including lung cancer and breast cancer. In previous work, we cloned and identified the human RAS association domain family 1A gene (RASSF1A) from the lung tumor suppressor locus 3p21.3. The CpG island and promoter region of RASSF1A is highly methylated in primary lung and breast tumors. In this study, we analyzed the methylation status of the promoter region of RASSF1A in 3 different tumor types: colon, ovarian and renal cell carcinoma. In colon cancers, 3 out of 26 tumor tissues (12%) were methylated at the CpG island of the RASSF1A gene. Renal and ovarian cancers showed a much higher frequency of methylation. For ovarian tumors, 8 out of 20 tumors (40%) were methylated. In renal cell carcinomas, 18 out of 32 cases (56%) were methylated. For all tumor types, none of the available normal tissues was methylated. This data suggests that methylation of the CpG island and promoter of the RASSF1A gene is common not only in lung and breast tumors but also in renal cell carcinoma and ovarian cancer. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11668500     DOI: 10.1002/ijc.1466

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  40 in total

1.  RASSF1A promoter methylation and Kras2 mutations in non small cell lung cancer.

Authors:  Jie Li; Zhongqiu Zhang; Zunyan Dai; Anthony P Popkie; Christoph Plass; Carl Morrison; Yian Wang; Ming You
Journal:  Neoplasia       Date:  2003 Jul-Aug       Impact factor: 5.715

Review 2.  Epigenetics of kidney cancer and bladder cancer.

Authors:  Amanda M Hoffman; Paul Cairns
Journal:  Epigenomics       Date:  2011-02       Impact factor: 4.778

3.  Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer.

Authors:  Joseph Kwong; Ji-Young Lee; Kwong-Kwok Wong; Xiaofeng Zhou; David T W Wong; Kwok-Wai Lo; William R Welch; Ross S Berkowitz; Samuel C Mok
Journal:  Neoplasia       Date:  2006-04       Impact factor: 5.715

4.  Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors.

Authors:  Thomas E Liggett; Anatoliy Melnikov; Qilong Yi; Charles Replogle; Wei Hu; Jacob Rotmensch; Aparna Kamat; Anil K Sood; Victor Levenson
Journal:  Gynecol Oncol       Date:  2010-11-06       Impact factor: 5.482

5.  Aberrant promoter methylation of the RASSF1A and APC genes in epithelial ovarian carcinoma development.

Authors:  Rahul Bhagat; Shilpa Chadaga; C S Premalata; G Ramesh; C Ramesh; V R Pallavi; Lakshmi Krishnamoorthy
Journal:  Cell Oncol (Dordr)       Date:  2012-10-10       Impact factor: 6.730

6.  Clinical implications of promoter hypermethylation in RASSF1A and MGMT in retinoblastoma.

Authors:  Kwong Wai Choy; Tom C Lee; Kin Fai Cheung; Dorothy S P Fan; Kwok Wai Lo; Katherine L Beaverson; David H Abramson; Dennis S C Lam; Christopher B O Yu; Chi Pui Pang
Journal:  Neoplasia       Date:  2005-03       Impact factor: 5.715

Review 7.  Epigenetics in ovarian cancer.

Authors:  Yanina Natanzon; Ellen L Goode; Julie M Cunningham
Journal:  Semin Cancer Biol       Date:  2017-08-03       Impact factor: 15.707

8.  Epigenetic reactivation of RASSF1A by phenethyl isothiocyanate (PEITC) and promotion of apoptosis in LNCaP cells.

Authors:  Sarandeep S S Boyanapalli; Wenji Li; Francisco Fuentes; Yue Guo; Christina N Ramirez; Ximena-Parades Gonzalez; Douglas Pung; Ah-Ng Tony Kong
Journal:  Pharmacol Res       Date:  2016-11-03       Impact factor: 7.658

9.  Methylation status of the APC and RASSF1A promoter in cell-free circulating DNA and its prognostic role in patients with colorectal cancer.

Authors:  Dimitrios Matthaios; Ioanna Balgkouranidou; Anastasios Karayiannakis; Helen Bolanaki; Nikolaos Xenidis; Kyriakos Amarantidis; Leonidas Chelis; Konstantinos Romanidis; Aikaterini Chatzaki; Evi Lianidou; Grigorios Trypsianis; Stylianos Kakolyris
Journal:  Oncol Lett       Date:  2016-06-01       Impact factor: 2.967

10.  Novel complex integrating mitochondria and the microtubular cytoskeleton with chromosome remodeling and tumor suppressor RASSF1 deduced by in silico homology analysis, interaction cloning in yeast, and colocalization in cultured cells.

Authors:  Leyuan Liu; Vo Amy; Guoqin Liu; Wallace L McKeehan
Journal:  In Vitro Cell Dev Biol Anim       Date:  2002 Nov-Dec       Impact factor: 2.416

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.